Mirum Pharmaceuticals annual ebitda
2019
2020
2021
2022
2023
2024
2025
Mirum Pharmaceuticals EBITDA Growth & History (MIRM)
Mirum Pharmaceuticals's calculated EBITDA was $2.1M for fiscal 2025.
View full Mirum Pharmaceuticals company overviewMirum Pharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.1M | $66.1M | — |
| 2024 | 2024-12-31 | −$64.0M | $34.3M | — |
| 2023 | 2023-12-31 | −$98.3M | $29.7M | — |
| 2022 | 2022-12-31 | −$128.0M | $44.8M | — |
| 2021 | 2021-12-31 | −$172.8M | −$68.8M | — |
| 2020 | 2020-12-31 | −$104.0M | −$49.4M | — |
| 2019 | 2019-12-31 | −$54.6M | — | — |
Mirum Pharmaceuticals quarterly ebitda
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$35.6M | −$36.7M | — |
| Q1 2026 | 2026-03-31 | −$782.6M | −$773.5M | — |
| Q4 2025 | 2025-12-31 | $1.5M | $19.7M | — |
| Q3 2025 | 2025-09-30 | $8.7M | $15.3M | — |
| Q2 2025 | 2025-06-30 | $1.1M | $19.4M | — |
| Q1 2025 | 2025-03-31 | −$9.1M | $11.7M | — |
| Q4 2024 | 2024-12-31 | −$18.2M | $8.9M | — |
| Q3 2024 | 2024-09-30 | −$6.6M | $15.9M | — |
| Q2 2024 | 2024-06-30 | −$18.4M | $4.6M | — |
| Q1 2024 | 2024-03-31 | −$20.8M | $5.0M | — |
| Q4 2023 | 2023-12-31 | −$27.1M | $5.9M | — |
| Q3 2023 | 2023-09-30 | −$22.5M | $9.3M | — |
| Q2 2023 | 2023-06-30 | −$22.9M | $7.9M | — |
| Q1 2023 | 2023-03-31 | −$25.8M | $6.6M | — |
| Q4 2022 | 2022-12-31 | −$33.0M | $12.3M | — |
| Q3 2022 | 2022-09-30 | −$31.8M | $11.0M | — |
| Q2 2022 | 2022-06-30 | −$30.8M | $6.5M | — |
| Q1 2022 | 2022-03-31 | −$32.4M | $15.1M | — |
| Q4 2021 | 2021-12-31 | −$45.2M | −$8.4M | — |
| Q3 2021 | 2021-09-30 | −$42.7M | −$21.1M | — |
| Q2 2021 | 2021-06-30 | −$37.3M | −$13.8M | — |
| Q1 2021 | 2021-03-31 | −$47.5M | −$25.6M | — |
| Q4 2020 | 2020-12-31 | −$36.9M | −$18.3M | — |
| Q3 2020 | 2020-09-30 | −$21.6M | −$5.8M | — |
| Q2 2020 | 2020-06-30 | −$23.5M | −$9.5M | — |
| Q1 2020 | 2020-03-31 | −$22.0M | −$15.8M | — |
| Q4 2019 | 2019-12-31 | −$18.6M | — | — |
| Q3 2019 · Sep 30 | 2019-09-30 | −$15.8M | — | — |
| Q2 2019 | 2019-06-30 | −$14.0M | — | — |
| Q1 2019 | 2019-03-31 | −$6.2M | — | — |
Mirum Pharmaceuticals ebitda trends
Over the last five fiscal years, Mirum Pharmaceuticals's ebitda increased from −$104.0M to $2.1M, a change of $106.1M. The latest reported quarter, Q2 2026, shows −$35.6M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Mirum Pharmaceuticals source filings ↗Community posts
Mirum’s hepatitis-delta drug succeeds in Phase 3 AZURE-1
Mirum Pharmaceuticals ($MIRM) said brelovitug met the primary endpoint in the Phase 3 portion of AZURE-1, which enrolled 153 treatment-naive patients with chronic hepatitis delta. At 24 weeks, the combined viral-response and liver-enzyme-no ...
